FibroGen, Inc (FGEN) Financials
FGEN Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 423.5 million | 585.7 million |
2023-09-30 | 460.4 million | 575.6 million |
2023-06-30 | 515.1 million | 575.4 million |
2023-03-31 | 538.5 million | 567.4 million |
FGEN Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -18.6 million | 9.3 million |
2023-09-30 | -85.2 million | 9.5 million |
2023-06-30 | -111.6 million | 15.9 million |
2023-03-31 | -102.2 million | 16.1 million |
FGEN Net Income
No data available :(
FGEN Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 235.6 million | - | 80.6 million |
2023-09-30 | 251.3 million | - | 81.9 million |
2023-06-30 | 335.7 million | 71.4 million | 84.8 million |
2023-03-31 | 355.9 million | - | 86.8 million |
FGEN Shares Outstanding
FGEN Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 251000 | 51.7 million | 24.2 million | - |
2023-09-30 | 684000 | 61.2 million | 25.6 million | - |
2023-06-30 | 993000 | 95.5 million | 31.2 million | - |
2023-03-31 | 591000 | 74.5 million | 34.3 million | - |
FGEN Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 27.1 million | 5.4 million |
2023-09-30 | 40.1 million | 4.2 million |
2023-06-30 | 44.3 million | 5.7 million |
2023-03-31 | 36.2 million | 3.5 million |
FGEN
Price: $1.13
52 week price:
Payout Ratio Range:
Earnings Per Share: -2.92 USD
P/E Ratio: -0.89
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 1.0 million
Ebitda: -33.4 millionMarket Capitalization: 136.3 million